Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism

  • Technology appraisal guidance
  • TA287
  • Published: 
Download guidance (PDF)

10 Sources of evidence considered by the Committee

A The Evidence Review Group (ERG) report for this appraisal was prepared by Southampton Health Technology Assessments Centre (SHTAC):

  • Copley V, Pickett K, Cooper K et al. Rivaroxaban for the treatment of pulmonary embolism and the prevention of recurrent venous thromboembolism. A single technology appraisal. February 2013

B The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope. Organisations listed in I were also invited to make written submissions. Organisations listed in II gave their expert views on rivaroxaban by providing a written statement to the Committee. Organisations listed in I, II and III have the opportunity to appeal against the final appraisal determination.

I. Manufacturer/sponsor

  • Bayer (rivaroxaban)

II. Professional/specialist and patient/carer groups:

  • AntiCoagulation Europe (ACE)

  • British Society for Haematology

  • British Society for Haemostasis and Thrombosis

  • Clinical Leaders of Thrombosis (CLOT)

  • Lifeblood: The Thrombosis Charity

  • Royal College of Nursing

  • Royal College of Pathologists

  • Royal College of Physicians

  • United Kingdom Clinical Pharmacy Association

  • Vascular Society

III. Other consultees:

  • Department of Health

  • Welsh Government

IV. Commentator organisations (did not provide written evidence and without the right of appeal):

  • Commissioning Support Appraisals Service

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • Healthcare Improvement Scotland

  • National Clinical Guidelines Centre

  • National Institute for Health Research Health Technology Assessment Programme

  • Southampton Health Technology Assessment Centre, University of Southampton

C The following individuals were selected from clinical specialist and patient expert nominations from the consultees and commentators. They gave their expert personal view on rivaroxaban by providing oral evidence to the Committee.

  • Dr David Bevan, Consultant Haematologist and Clinical Lead in Haemostasis, nominated by organisation representing Royal College of Pathologists and British Society for Haematology – clinical specialist

  • Dr Mark Crowther, Consultant Haematologist, nominated by organisation representing British Society of Haemostasis and Thrombosis – clinical specialist

  • Mrs Annya Stephens-Boal, Executive Officer of Lifeblood: The Thrombosis Charity, nominated by organisation representing Lifeblood: The Thrombosis Charity – patient expert

D Representatives from the following manufacturer/sponsor attended Committee meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy.

  • Bayer